Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez et al. · The Lancet Oncology · 2018
Cited by 1,395 works. doi:10.1016/s1470-2045(18)30700-9
Authors
- Frank Stephen Hodi
- Vanna Chiarion‐Sileni
- Rene C. Gonzalez
- Jean‐Jacques Grob
- Piotr Lukasz Rutkowski
- Charles Lance Cowey
- Christopher D. Lao
- Dirk Schadendorf
- John D. Wagstaff
- Reinhard Dummer
- Pier Francesco Ferrucci
- Michael Smylie
- David Hogg
- Iván Márquez‐Rodas
- Joel Jiang
- Jasmine I. Rizzo
- James Larkin
- Jedd D. Wolchok
References
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
- Immune Checkpoint Blockade in Cancer Therapy
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials